CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle
Therapeutics, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle™)
product platform, announced today the appointment of Pierre Legault,
MBA, CPA, as a Director and Chairman of the Board of Directors. Mr.
Legault brings to Bicycle more than 35 years of executive leadership
experience in the biopharmaceutical industry. He replaces Stephen J.
Hoffman, M.D., Ph.D., as Chairman.
“I am excited to have Pierre join the Bicycle team. His broad experience
in biopharma leadership will be tremendously valuable for us as our
clinical pipeline matures,” said Kevin Lee, Ph.D., Chief Executive
Officer of Bicycle Therapeutics. “As we welcome Pierre, we also thank
Steve for his guidance and leadership through a period of rapid growth
at Bicycle over the last three years, helping us to successfully evolve
the company into a clinical stage organization, complete two financings,
establish a strong U.S. presence and develop a broad, differentiated
product pipeline of Bicycle-based therapeutics.”
“I’m honored to accept this Chairman role,” said Mr. Legault. “Bicycle’s
technology is truly unique, and I look forward to working closely with
the team and the rest of the Board to advance our work in oncology and
other diseases.”
Mr. Legault also currently serves as the Chairman of Poxel, a
biopharmaceutical company developing innovative drugs for metabolic
diseases, including type 2 diabetes and non-alcoholic steatohepatitis.
He is Chairman of Artios, a DNA damage repair company. He is also a
member of the Board of Directors of Clementia Pharmaceuticals, Urovant
Sciences and Syndax Pharmaceuticals. In the past, he was a member of the
Board of Directors at Forest Laboratories, Tobira Therapeutics, NPS
Pharmaceuticals, Regado Biosciences, Armo Biosciences, Iroko
Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy and
Nephrogenex, where he also served as the Chairman and CEO from 2012 to
2016. From 2010 to 2012, he served as the CEO of Prosidion. From 2009 to
2010, he served as the CFO and Treasurer of OSI Pharmaceuticals. Mr.
Legault also served as the CEO of Eckerd Pharmacy and Senior Executive
Vice President and CAO of the Rite Aid Corporation. Between 1989 and
2005, he held various global roles such as President, CEO and CFO of
global group at Sanofi and legacy companies. Mr. Legault studied at
McGill University, HEC Montreal and Harvard Business School.
About Bicycle Therapeutics
Bicycle Therapeutics is developing a unique class of chemically
synthesized medicines based on its proprietary bicyclic peptide (Bicycle™)
product platform to address therapeutic needs unreachable with existing
treatment modalities. Bicycle’s internal focus is in oncology, where the
company is developing targeted cytotoxics (Bicycle Toxin Conjugates™),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and highly
selective targeting deliver rapid tumor penetration and retention while
clearance rates and routes of elimination can be tuned to minimize
exposure of healthy tissue and bystander toxicities. The company’s lead
program, BT1718, is being evaluated in a Phase I/IIa trial in
collaboration with Cancer Research UK. The company’s unique intellectual
property is based on the work initiated at the MRC Laboratory of
Molecular Biology in Cambridge, U.K., by the scientific founders of the
company, Sir Greg Winter, a winner of the Nobel Prize in Chemistry for
his pioneering work in phage display of peptides and antibodies, and
Professor Christian Heinis. Bicycle has its headquarters in Cambridge,
U.K., with many key functions and members of its leadership team located
in the biotech hub of Boston, Mass. For more information, visit www.bicycletherapeutics.com
or follow us on Twitter at @Bicycle_tx.
Contacts
Media:
Ten Bridge Communications
Sara Green sgreen@tenbridgecommunications.com
+1-617-233-1714
Investors:
Argot Partners
Maeve Conneighton maeve@argotpartners.com
+1-212-600-1902